New Virus-Based therapy enters human trials for deadly brain cancer

NCT ID NCT06504381

Summary

This study is testing whether adding two new drugs, DB107-RRV and DB107-FC, to standard brain cancer treatment helps patients live longer without their cancer worsening. The trial will enroll 70 adults with newly diagnosed aggressive brain tumors who are having surgery. Researchers will first check the safety of the new drug combination, then measure how long patients stay progression-free compared to historical data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwell Health

    RECRUITING

    Lake Success, New York, 11042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California, San Diego

    RECRUITING

    San Diego, California, 92093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Southern California

    RECRUITING

    Los Angeles, California, 90089, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.